Researchers at Texas A&M Health have identified a molecular mechanism that increases cholesterol levels inside prostate ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager". This type of immunotherapy ignites our own ...

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

(HealthDay News) — Low testosterone levels may increase the risk of higher-grade “extreme” progression of prostate cancer among men enrolled in active surveillance (AS), according to a study published ...

After decades of overtreatment for low-risk prostate cancer and inadequate management of its more aggressive forms, patients are now more likely to receive medical care matched to level of risk, ...

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

Better continence, erectile function, but data on oncologic outcomes still 2 years away ...

In a recent study published in the British Journal of Sports Medicine, researchers investigate the relationship between changes in adult cardiorespiratory fitness (CRF) and the incidence and mortality ...

Results challenge view that high testosterone fuels prostate cancer growth ...

Add Yahoo as a preferred source to see more of our stories on Google. Researchers say they've developed a urine test that could answer whether prostate cancer is aggressive and requiring immediate ...

Editor's note: second of two parts; read part one here.. In the first part of our series, we described how PSA is used as a screening tool to help detect prostate cancer in men who don't have symptoms ...